Skip to content
GLP-1 Calculators

Wegovy Cost in 2026 — Real Monthly Prices, Savings Card & Vial Self-Pay

Your real monthly Wegovy cost across every 2026 access path — insurance copay, the $0 Novo savings card, NovoCare's $499 self-pay vials, cash, and compounded semaglutide.

Updated April 2026

Medical disclaimer: This tool is for informational purposes. Not medical advice. Consult your healthcare provider before starting, stopping, or changing any medication. Drug prices, savings cards, and coverage policies change frequently — verify current pricing directly with the manufacturer or your pharmacy.

Your inputs

Results

Monthly
$25
$300/year

2026 Wegovy price at a glance

Novo Nordisk lists Wegovy at $1,349.02 per 28-day supply in 2026 (any dose strength, 4-pen box). The real price you pay depends on exactly one thing: which access path your situation supports.

  • Commercial insurance + Novo savings card: $0–$25/month. If your employer or marketplace plan covers Wegovy, the savings card brings a covered copay to $0 with a maximum benefit of $225 off per 28-day supply and a $3,500 annual cap. For a $200 copay plan, that is essentially free Wegovy for the first 15 fills of the year, then $200/month after.
  • NovoCare self-pay vial: $499/month. Launched in 2025, available in 2026 for 1.7mg and 2.4mg strengths only. No insurance involved. Cash, HSA, or FSA — delivered by mail.
  • Novo savings card without coverage: $500/month.Roughly matches NovoCare vial pricing but delivers branded pens. Useful if you need starter doses (0.25mg, 0.5mg, 1mg, 1.7mg) that vials don’t yet cover.
  • Cash pay at pharmacy: $1,300–$1,400/month. GoodRx and SingleCare rarely bring Wegovy below $1,250. The worst financial path in 2026 — always compare to NovoCare vials and the savings card first.
  • Compounded semaglutide: $199–$349/month with individual medical necessity. The mass-market $200 compounded path is largely closed post-shortage. Regulatory and sourcing risk is real.

The NovoCare vial details most pages miss

NovoCare’s self-pay Wegovy vials shipped in late 2025 specifically to compete with Eli Lilly’s LillyDirect Zepbound vials. A few things the marketing doesn’t emphasize:

  • Only 1.7mg and 2.4mg are available at $499/month. Starter doses (0.25mg, 0.5mg, 1mg) still require a branded pen prescription from retail.
  • Each vial is multi-dose and requires a syringe. If you are needle-averse or unfamiliar with drawing up a dose, the single-use pen (covered by the savings card) is easier to use.
  • Dollars spent do not apply to your health plan’s deductible or out-of-pocket maximum — it’s a cash-pay program.
  • HSA and FSA funds are eligible because Wegovy is FDA-approved for a medical indication.

For patients already at maintenance dose with no insurance coverage, NovoCare vials are typically the right call. For patients still titrating, the savings card or insurance path works better until you reach 1.7mg.

How Wegovy coverage decisions actually play out

Commercial plans fall into three buckets:

  1. Covers AOMs broadly (~35–45% of large-employer plans in 2026): prior auth required, but approval is routine with BMI 30+ or BMI 27+ with one weight-related comorbidity. Expect $0–$50 copay with the savings card.
  2. Covers Wegovy only for the SELECT indication (~20% of plans): patients with established cardiovascular disease + overweight/obesity qualify. Everyone else denies.
  3. No AOM coverage at all (~35–40% of plans): Wegovy is non-formulary. NovoCare vials or compounded tirzepatide via Zepbound-equivalent paths are your only realistic options.

Medicare Part D adopted Wegovy coverage in 2025 for the SELECT indication only. Medicaid coverage varies — California, Pennsylvania, and Massachusetts have broader AOM coverage; most other states remain restrictive.

Wegovy vs Zepbound — the honest 2026 answer

If you have strong insurance coverage, the drugs cost the same ($0–$50 with a savings card) and the choice comes down to efficacy (Zepbound averages ~21% total body weight loss vs ~15% for Wegovy in head-to-head SURMOUNT-5 data) and side-effect tolerance. If you are paying cash, Zepbound’s LillyDirect vials ($349 for 2.5mg starter, $499 for maintenance) edge out NovoCare ($499 for maintenance only). Use the Wegovy vs Zepbound comparison for your specific starting weight and desired monthly budget.

Budgeting for the long haul

Weight lost on Wegovy is reclaimed at about two-thirds within 12 months of stopping (STEP-4 data). Plan for indefinite maintenance. A realistic 5-year budget assumption for an insured patient with the savings card: year one at $0–$1,200, years 2–5 at roughly $50–$300/month once the $3,500 annual card benefit is exhausted and copays reset. Run the maintenance-dose cost calculator with your specific plan.

Related tools
Zepbound cost calculator
LillyDirect $499 vials and the Zepbound savings card.
Wegovy vs Zepbound
SURMOUNT-5 efficacy plus cost per pound.
Ozempic cost calculator
Same molecule, diabetes label, different coverage.
Vial vs pen comparison
NovoCare and LillyDirect vials vs branded pens.
Will insurance cover Wegovy?
Coverage likelihood by plan type and diagnosis.
Prior auth and appeal guide
First-pass approval odds plus an appeal checklist.

Frequently asked questions

How much does Wegovy cost without insurance in 2026?

Novo Nordisk's 2026 list price for Wegovy is about $1,349 per month for a 4-pen box (any dose strength). NovoCare launched a self-pay vial program in 2025 that prices Wegovy vials at around $499/month for 1.7mg and 2.4mg doses — a direct response to Eli Lilly's LillyDirect Zepbound vials. Cash pay at a pharmacy without any program typically lands at $1,300–$1,400/month.

Is the $0 Wegovy savings card still available in 2026?

Yes, for commercially insured patients whose plan covers Wegovy. The Novo Nordisk Wegovy savings card brings covered commercial copays to as little as $0/month (maximum benefit of $225 off per 28-day supply, $3,500 annual cap). If your commercial plan does not cover Wegovy, the same card offers a $500/month cash-pay discount — competitive with the NovoCare $499 vial option but not better. The card is not valid with Medicare, Medicaid, TRICARE, or VA.

NovoCare $499 Wegovy vials — what's the catch?

NovoCare self-pay vials ship directly to your door with a telehealth-style prescription flow. As of Q1 2026, only the 1.7mg and 2.4mg strengths (the top two maintenance doses) are available at $499/month. You still need a valid prescription from a licensed provider. You need to be comfortable drawing a dose from a multi-dose vial with a syringe (not the single-use pen most Wegovy patients start with). NovoCare is cash-pay only — it does not run through your insurance, so dollars spent do not count toward your deductible or out-of-pocket max.

Wegovy vs Zepbound cost in 2026 — which is cheaper?

Cash-pay path, Zepbound wins. LillyDirect Zepbound vials start at $349 for 2.5mg and cap at $499/month for 5–15mg, while NovoCare Wegovy vials are only available at $499 and only for the top two doses. Covered copay path, they're similar — both offer savings cards that can bring covered copays to $0–$25/month. Cost per pound lost, Zepbound generally wins based on SURMOUNT-5 head-to-head data (Zepbound delivered about 20% more weight loss than Wegovy at max doses). Run the wegovy-vs-zepbound calculator for your specific inputs.

Is compounded semaglutide cheaper than Wegovy in 2026?

On sticker price, yes — compounded semaglutide runs $199–$349/month through telehealth clinics, versus $499–$1,349 for branded Wegovy. But the FDA removed semaglutide from the drug shortage list in late 2024, ending the broad 503A compounding pathway for weight loss. By 2026, legitimate compounded semaglutide is limited to individual medical necessity (documented allergy to a branded inactive ingredient, for example). Platforms still selling $199/month compounded semaglutide for general weight loss are operating outside FDA guidance. Factor the regulatory risk, sourcing uncertainty, and lack of FDA oversight into the savings before you commit.

Will my insurance cover Wegovy if I don't have diabetes?

It depends on your plan and employer. Commercial plans that cover 'anti-obesity medications' (AOMs) with a BMI 30+ or BMI 27+ with one comorbidity typically require prior authorization. About 40–50% of large employer commercial plans covered Wegovy in 2025; that share grew modestly into 2026. Medicare Part D covers Wegovy only when prescribed for the FDA-approved SELECT indication (established cardiovascular disease + overweight/obesity). Medicaid coverage varies by state. Run our insurance coverage checker for a quick estimate, then use the prior-auth guide if you need to appeal.

How long do I need to stay on Wegovy after reaching goal weight?

Wegovy is a chronic weight-management therapy. STEP-4 withdrawal data showed patients regained about two-thirds of lost weight within 12 months of stopping. Treat Wegovy as indefinite maintenance, not a 12-month program. Budget accordingly — a $0 copay with a $3,500/year savings-card cap works for your first year on most plans, but maintenance budgeting needs to assume savings-card exhaustion plus ongoing specialty-tier copays.

Is my data stored anywhere when I use this calculator?

No. Every number you enter stays in your browser — nothing is sent to a server, logged, or transmitted to any third party. The tool is purely a client-side calculation.

Digital Dashboard Hub

Track your GLP-1 progress, weight loss, and health metrics

DDH has 54 health and wellness trackers — weight loss logs, BMI history, symptom tracking, and habit tools — built for your GLP-1 journey. Free 14-day trial.

Track your GLP-1 journey free →
Part of the Digital Dashboard Hub network
Powered byDigital Dashboard Hub— 250+ free tools

Calculators, trackers, and planners for creators, business, and wellness — all in one place.

Explore all 250+ tools →